Summary of January 21 Teleconference with FDA Regarding Colchicine
January 21, 2010
The ACR is aware that the FDA recently removed unapproved colchicine from the market. The ACR sent a letter to Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research at the Food and Drug Administration and a rheumatologist, expressing the College’s concerns on the market removal of unapproved colchicine.
The College strongly encourages the Food and Drug Administration to grandfather unapproved colchicine and grant market approval to unapproved colchicine so that patients can continue to access this vital inexpensive treatment.
If you have any questions about the College’s efforts, please contact the Government Affairs Department at 404-633-3777 or .
